Home  >  World-leading research: fighting against brain tumours

Support the research and development of cancer therapies to fight brain tumours

You can help us to develop novel brain cancer-specific therapies that can substantially increase the survival and the life quality of patients with brain cancer.

Dr. Julius W. Kim’s focus is to rapidly translate therapeutic approaches into the clinic. The projects he is working on include:

  • Generation of cell-specific adenoviral vectors that can work as an efficient delivery system or cancer-specific killing machinery.
  • A brain cancer vaccine therapy that can provoke and boost our immune system to fight against brain tumours.
  • A viro-immunotherapy that can exclusively kill cancerous cells and boost immunity against brain cancer.
Donate to this project
Researcher in lab

Why support this project?

Despite many advanced therapies, the survival rate of this deadly disease remains extremely poor, and this disease kills more Australian children than any other diseases. New efficient therapies are urgently in need.

Dr. Kim’s team developed new brain cancer-specific therapeutic approaches that have never been explored but have a high potential to substantially increase the survival of patients with brain tumours.

With our novel therapeutic strategies and our devoted translational research team, we expect to improve the treatment outcome of brain tumour patients within five years, firstly in Australia.

PROJECT 1: Bioengineered dendritic cell-based cancer vaccine against brain tumours

We developed a novel cancer vaccine approach by bioengineering dendritic cells (DCs), our body’s orchestrator of immune cells, with an adenoviral vector.

Our bioengineered DCs can orchestrate and boost the activities of immune cells against brain cancerous cells to ‘efficiently and specifically’ kill cancerous cells with a single shot.

PROJECT 2: Combinatory viro-immunotherapy

Although there was a promising clinical outcome in the USA (over fivefold increased survival rate), there has been a lack of clinical uses with viro-immunotherapies in Australia.

We developed a unique viro-immunotherapeutic vector that selectively kills tumour cells while inducing and boosting anti-tumour immune responses simultaneously.

Donate to this project

“With our new brain cancer-specific therapeutic approaches, we aim to improve the treatment outcome of Australian brain tumour patients within five years.”

Dr. Julius W. Kim

Why support Dr Julius W. Kim’s research

Dr. Kim has:

  • Unique skill sets to genetically modify an adenoviral vector. Only a handful of researchers around the world can do well-designed genetic modifications to achieve maximum efficacy.
  • Extensive translational research experience from forming novel ideas with his patentable vectors (bench side) to translating into clinical trials (bedside).

Importantly, he works with a devoted and enthusiastic research team at the Kolling Institute and Royal North Shore Hospital.

Dr. Julius W. Kim

Dr. Kim is a leader of the viro-immunotherapy (brain cancer vaccine) program at the Kolling Institute. He was trained at Washington University in St. Louis, University of Chicago, and Northwestern University, researching immunotherapies (cancer vaccination and targeted oncolytic virotherapy and antibody-based therapies) and genetherapies. After moving to Australia, Dr. Kim has contributed to various brain tumour translational research programs and is currently leading a multi-institutional research program with the goal to develop novel vector-mediated therapies against brain tumours including brain cancer vaccination and targeted oncolytic viro-immunotherapy.

How much would you like to donate?

Your donation will help develop novel brain cancer-specific therapies that can substantially increase the survival and the life quality of patients with brain cancer.

< Go back

< Go back

$
$
$